In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against Gram-positive clinical isolates from cancer patients

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 2, 1996, Pages 265-269

  Rolston, K V I ^a   Dholakia, N ^a   Ho, D H ^a   LeBlanc, B ^a   Dvorak, T ^a   Streeter, H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RAMOPLANIN; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS CEREUS; CANCER PATIENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN;

EID: 0029768089     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.2.265     Document Type: Article

References (10)

1. Bartoloni, A., Colao, M. G., Orsi, A., Dei, R., Giganti, E. & Parenti, F. (1990). In vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. Journal of Antimicrobial Chemotherapy 26, 627-33.
2. Collins, L. A., Eliopoulos, G. M., Wennerstein, C. B., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of ramoplanin against vancomycin-resistant Gram-positive organisms. Antimicrobial Agents and Chemotherapy 37, 1364-6.
3. Facklam, R. R. & Washington, J. A. I. (1991). Streptococcus and related catalase-negative gram positive cocci. In Manual of Clinical Microbiology (Balows, A., Hausler, W. J., Herrmann, K., Isenberg, H. D. & Shadomy, H. J., Eds), pp. 238-57. American Society for Microbiology. Washington, DC.
4. Hughes, W. T., Armstrong, D., Bodey, G. P., Feld, R., Mandell, G. L., Meyers, J. D. et al. (1990). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161, 381-96.
5. Johnson, C. C., Taylor, S., Pitsakis, P., May, P. & Levison, M. E. (1992). Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrobial Agents and Chemotherapy 36, 2342-5.
6. Jones, R. N. & Barry, A. L. (1989). In vitro evaluation of ramoplanin (A-16686 or MDL 62198). A new depsipeptide complex for potential topical use. Diagnostic Microbiology and Infectious Diseases 12, 279-82.
7. Kloos, W. E. & Wolfshol, J. F. (1982). Identification of Staphylococcus species with the API STAPH-IDENT system. Journal of Clinical Microbiology 16, 509-16.
8. Koll, B. S. & Brown, A. E. (1993). The changing epidemiology of infections at cancer hospitals. Clinical Infectious Diseases 17, Suppl. 2, S322-8.
9. Lawrence, T., Rotstein, C., Beam, T. R., Gorznski, E. A. & Amsterdam, D. (1993). In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Antimicrobial Agents and Chemotherapy 37, 896-900.
10. National Committee for Clinical Laboratory Standards (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Second Edition - Approved Standard M7-A2. NCCLS, Villanova, PA.